Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is making strides in the development of Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (MS). Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and is preparing for a Phase 2 clinical trial following successful completion of Phase 1 safety studies and key toxicology programs.

The advancement of Lucid-MS represents a potential shift in MS treatment, as current therapies often focus on modulating the immune response rather than directly addressing myelin damage. More than a decade of preclinical research supports Lucid-MS, including studies showing preservation of myelin integrity, reduced degradation, and improved functional recovery in animal models. This mechanism of action could offer new hope for patients by potentially slowing or reversing the progression of disability associated with MS.

Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients. This tool could help evaluate the effectiveness of remyelinating therapies, providing a crucial biomarker for clinical trials and eventually for patient monitoring. The development of such imaging technology could accelerate the approval process for Lucid-MS and other remyelinating drugs by offering a direct measure of therapeutic impact.

The editorial also highlighted recent clinical and regulatory developments from other major pharmaceutical companies, including Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX), and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune, immune-mediated, and chronic inflammatory disease treatment markets. This competitive landscape emphasizes the significance of Quantum BioPharma’s differentiated approach with Lucid-MS.

Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets UNBUZZD, an over-the-counter product, and receives royalty payments from sales. For more information, visit the company’s newsroom at https://ibn.fm/QNTM.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis.

The post Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis appeared first on citybuzz.